BridgeBio Pharma, Inc. (BBIO) filed a New Drug Application (NDA) with the U.S. Food and Drug Administration on March 30 2026 for its oral small‑molecule therapy BBP‑418, intended to treat limb‑girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The filing marks the first regulatory step toward a potential first‑in‑class treatment for this rare neuromuscular disorder.
The NDA follows the Phase 3 FORTIFY trial, which enrolled 112 patients and reported that BBP‑418 met all primary and secondary endpoints in a 12‑month interim analysis. Improvements were seen in the 100‑meter timed test, forced vital capacity, and a rapid, sustained reduction in serum creatine kinase levels. Safety data showed a tolerability profile comparable to placebo, supporting the drug’s clinical benefit.
BridgeBio estimates the U.S. and EU market for LGMD2I/R9 at more than $1 billion, with analysts projecting worldwide sales of $1.1 billion by 2035. A successful approval would position BBP‑418 as a major growth driver for the company, complementing its existing product Attruby and expanding its portfolio in the neuromuscular space.
BBP‑418 has already earned Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA, and an Orphan Drug designation from the European Medicines Agency. The Fast Track status could qualify the NDA for priority review, potentially shortening the regulatory timeline and accelerating market entry.
Christine Siu, CEO of BridgeBio Neuromuscular, said, "This NDA submission brings us one step closer to delivering the first approved therapy to individuals and families affected by LGMD2I/R9, a severe, progressive neuromuscular disease. This achievement not only reflects the strength of the data, but also our dedicated focus on addressing the urgency of a community that has long been waiting for meaningful treatment options. We are committed to working closely with the FDA to make this potential disease‑modifying therapy available as quickly as possible."
Dr. Katherine Mathews added, "People living with LGMD2I/R9 face a real unmet medical need. There is currently no specific treatment, the disease often has an early age of onset, and it is relentlessly progressive, leading to irreversible loss of motor function. The early separation from placebo on 100MTT is especially encouraging. In a progressive muscle disease where time matters, seeing early improvements in ambulation suggests a rapid onset of action of BBP‑418. The improved motor and pulmonary functions seen in this interim analysis, together with a favorable safety profile, provide strong support for the potential of BBP‑418 to be the first approved therapy for LGMD2I/R9."
Analysts at Mizuho Securities and Jefferies have expressed high confidence in the drug’s approval prospects, with Jefferies estimating a >90 % chance of full FDA approval by late 2026 or early 2027. The company’s guidance for a U.S. launch in late 2026 or early 2027 reflects the strong data and the regulatory designations that could expedite review.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.